The diagnosis and treatment of generalized anxiety disorder;Generalisierte Angststörung: Diagnostik und Therapie

Deutsches Arzteblatt International

Volumn 110, Issue 17, 2013, Pages 300-310

  Bandelow, Borwin ^a   Boerner, Reinhard J ^b   Kasper, Siegfried ^c   Linden, Michael ^b   Wittchen, Hans Ulrich ^d   Möller, Hans Jürgen ^e  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANXIOLYTIC AGENT; AZAPIRONE; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; HERBACEOUS AGENT; HOMEOPATHIC AGENT; HYDROXYZINE; IMIPRAMINE; OPIPRAMOL; PREGABALIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ADDICTION; ARTICLE; CLINICAL EFFECTIVENESS; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL (TOPIC); DIAGNOSTIC ERROR; EMOTIONALITY; GENERALIZED ANXIETY DISORDER; HEREDITY; HUMAN; INTERNET BASED COGNITIVE BEHAVIORAL THERAPY; INTERNET BASED THERAPY; NEUROBIOLOGY; PATIENT CARE; PERSONAL EXPERIENCE; PREVALENCE; PROBLEM SOLVING; PSYCHOANALYSIS; PSYCHODYNAMIC PSYCHOTHERAPY; PSYCHOEDUCATION; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; SHORT COURSE THERAPY; TREATMENT RESPONSE;

EID: 84906329044     PISSN: 18660452     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2013.0300     Document Type: Article

References (28)

1. Wittchen HU, Kessler RC, Beesdo K, Krause P, Hofler M, Hoyer J: Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry 2002;63(Suppl 8):24-34.
2. Wittchen HU, Jacobi F: Size and burden of mental disorders in Europe-a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol 2005;15:357-76.
3. Wittchen HU, Jacobi F, Rehm J: The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011;21:655-79.
4. Maier W, Linden M, Sartorius N: Psychische Erkrankungen in der Allgemeinpraxis. Ergebnisse und Schlußfolgerungen einer W HO-Studie. Dtsch Arztebl 1996;93(18):1202-6.
5. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE: Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:593-602.
6. Tyrer P, Seivewright H, Johnson T: The Nottingham Study of Neurotic Disorder: predictors of 12-year outcome of dysthymic, panic and generalized anxiety disorder. Psychol Med 2004;34:1385-94.
7. Kessler RC, Frank RG, Edlund M, Katz SJ, Lin E, Leaf P: Differences in the use of psychiatric outpatient services between the United States and Ontario. N Engl J Med 1997;336:551-7.
8. Bandelow B, Broocks A: Generalisierte Angststörungen - Hypothesen zur Ätiologie. In: Bandelow B (ed.): Angst- und Panikerkrankungen, 2nd edition. Bremen: UNI-MED, 2006:105-8.
9. Noyes R Jr., Clarkson C, Crowe RR, Yates WR, McChesney CM: A family study of generalized anxiety disorder. Am J Psychiatry 1987;144:1019-24.
10. Hettema JM, Prescott CA, Kendler KS: A population-based twin study of generalized anxiety disorder in men and women. J Nerv Ment Dis 2001;189:413-20.
11. Brawman-Mintzer O, Lydiard RB. Biological basis of generalized anxiety disorder. J Clin Psychiatry 1997;58:16-25; discussion 26.
12. Abelson JL, Glitz D, Cameron OG, Lee MA, Bronzo M, Curtis GC: Blunted growth hormone response to clonidine in patients with generalized anxiety disorder. Arch Gen Psychiatry 1991;48:157-62.
13. Tiihonen J, Kuikka J, Rasanen P, Lepola U, et al.: Cerebral benzodiazepine receptor binding and distribution in generalized anxiety disorder: a fractal analysis. Mol Psychiatry 1997;2:463-71.
14. Bandelow B, Zohar J, Hollander E, Kasper S, et al.: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J Biol Psychiatry 2008;9:248-312.
15. Lader M: Dependence and withdrawal: comparison of the benzodiazepines and selective serotonin re-uptake inhibitors. Addiction 2012;107:909-10.
16. Schweizer E, Rickels K, De Martinis N, Case G, Garcia-Espana F: The effect of personality on withdrawal severity and taper outcome in benzodiazepine dependent patients. Psychol Med 1998;28:713-20.
17. Kan CC, Breteler MH, Zitman FG: High prevalence of benzodiaze - pine dependence in out-patient users, based on the DSM-III-R and ICD-10 criteria. Acta Psychiatr Scand 1997;96:85-93.
18. Rickels K: Benzodiazepines in the treatment of anxiety. Am J Psychother 1982;36:358-70.
19. Donovan MR, Glue P, Kolluri S, Emir B: Comparative efficacy of antidepressants in preventing relapse in anxiety disorders-a metaanalysis. J Affect Disord 2010;123:9-16.
20. Walendzik A, Lux G, Wasem J, Jahn R: Studie des Lehrstuhls für Medizinmanagement an der Universität Duisburg-Essen im Auftrag der Deutschen Psychotherapeuten-Vereinigung 2011.
21. Ballenger JC, Davidson JRT, Lecrubier Y, Nutt DJ, et al.: Consensus statement on generalized anxiety disorder from the international consensus group on depression and anxiety. Journal of Clinical Psychiatry 2001;62(Suppl 11):53-8.
22. DIMDI. ICD-10-GM 2009 - Systematisches Verzeichnis: Internationale statistische Klassifikation der Krankheiten und verwandter Gesundheitsprobleme - 10. Revision - German Modification. Deutsches Institut für Medizinische Dokumentation und Information (DIMIDI). In: Graubner B (eds.). Köln: Deutscher Ärzte-Verlag, 2008.
23. Sartorius N, Üstün TB, Costa E Silva JA, Goldberg D, et al.: An international study of psychological problems in primary care. Preliminary report from the World Health Organization Collaborative Project on 'Psychological Problems in General Health Care'. Arch Gen Psychiatry 1993;50:819-24.
24. Wittchen HU, Kessler RC, Beesdo K, Krause P, Hofler M, Hoyer J: Generalized anxiety and depression in primary care: prevalence, recognition, and management. J Clin Psychiatry 2002;63(Suppl 8):24-34.
25. Sartorius N, Ustun TB, Lecrubier Y, Wittchen HU: Depression comorbid with anxiety: results from the WHO study on psychological disorders in primary health care. Br J Psychiatry Suppl 1996;30:38-43.
26. Bandelow B, Rudolf S, Reitt M, Wedekind D: Psychotherapie der Angsterkrankungen. In: Herpertz S, Schnell. K, Falkai P (eds.): Psychotherapie in der Psychiatrie. Stuttgart: Kohlhammer 2013.
27. Linden M: Generalisierte Angsterkrankungen. In: Batra A, Wassmann R, Buchkremer G, (eds.): Verhaltenstherapie. Grundlagen, Methoden, Anwendungsgebiete. Stuttgart: Thieme Verlag, 2012.
28. Baldwin DS, Stein DJ, Dolberg OT, Bandelow B: How long should a trial of escitalopram treatment be in patients with major depressive disorder, generalised anxiety disorder or social anxiety disorder? An exploration of the randomised controlled trial database. Hum Psychopharmacol 2009;24:269-75.